Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Inventory (2016 - 2025)

Cytosorbents (CTSO) has disclosed Inventory for 14 consecutive years, with $4.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Inventory rose 23.22% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Sep 2025, up 23.22%, and an annual FY2024 reading of $2.7 million, down 25.74% over the prior year.
  • Inventory was $4.0 million for Q3 2025 at Cytosorbents, up from $3.0 million in the prior quarter.
  • Across five years, Inventory topped out at $5.4 million in Q1 2022 and bottomed at $1.7 million in Q1 2023.
  • Average Inventory over 5 years is $3.6 million, with a median of $3.6 million recorded in 2022.
  • The sharpest move saw Inventory soared 123.59% in 2021, then plummeted 68.31% in 2023.
  • Year by year, Inventory stood at $4.8 million in 2021, then decreased by 27.37% to $3.5 million in 2022, then rose by 6.31% to $3.7 million in 2023, then fell by 25.74% to $2.7 million in 2024, then skyrocketed by 46.43% to $4.0 million in 2025.
  • Business Quant data shows Inventory for CTSO at $4.0 million in Q3 2025, $3.0 million in Q1 2025, and $2.7 million in Q4 2024.